Fig. 1A



142A2
Response (RU)
135
115
95
75
55
35
15
-5
50
150
250
350
450
550
Time (seconds)

Fig. 1B



142S38B
Response (RU)
135
115
95
75
55
35
15
-5
50
150
250
350
450
550
Time (seconds)

Fig. 2A



A. Agonist mode
% phospho-p65 positive
50
40
30
20
10
0
TL1A alone
A2-IgG1
A2-IgG2
A2- IgG4v

Fig. 2B



B. Antagonist mode
% phospho-p65 positive
60
40
20
0
+ TL1A
TL1A alone
A2-IgG1
A2-IgG2
A2-IgG4v

Fig. 3A



A. Agonist mode
% phospho-p65 positive
50
40
30
20
10
0
-4
-2
0
2
Log10[Ab] (μg/mL)
A2-IgG2
S38-IgG2
A2-IgG4v
S38-IgG4v

Fig. 3B



B. Antagonist mode
% phospho-p65 positive
60
40
20
0
-3
-2
-1
0
1
2
Log10[Ab] (μg/mL)
A2-IgG2
S38-IgG2
A2-IgG4v
S38-IgG4v

Fig. 4A



A. Agonist mode
A2-IgG2
S38-IgG2
IL-13 secretion (pg/mL)
2000
1500
1000
500
0
-1
0
1
2
3
Log10[Ab] (nM)

Fig. 4B



B. Antagonist mode
A2-IgG2
S38-IgG2
IL-13 secretion (pg/mL)
2000
1500
1000
500
0
-1
0
1
2
3
Log10[Ab] (nM)

Fig. 5A



A. Agonist mode
A2 IgG4
mv142A2
% phospho-p65 positive
80
60
40
20
0
-2
-1
0
1
2
3
Log10[Ab] (nM)

Fig. 5B



B. Antagonist mode
A2 IgG4
mv142A2
% phospho-p65 positive
80
60
40
20
0
-2
-1
0
1
2
3
Log10[Ab] (nM)

Fig. 6A



A. Agonist mode
S38B IgG4
mvS38B2
% phospho-p65 positive
30
20
10
0
-1
0
1
2
3
Log10[Ab] (nM)

Fig. 6B



B. Antagonist mode
S38B IgG4
mvS38B2
% phospho-p65 positive
60
40
20
0
-1
0
1
2
3
Log10[Ab] (nM)

Fig. 7A



A. Agonist mode
% phospho-p65 positive
60
40
20
0
-4
-2
0
2
Log10[Ab] (nM)
142A2 IgG2
142A2 IgG4null
142A2 4244
142A2 2422

Fig. 7B




B. Antagonist mode
% phospho-p65 positive
60
40
20
0
-4
-2
0
2
Log10[Ab] (nM)
142A2 IgG2
142A2 IgG4null
142A2 4244
142A2 2422

Fig. 8


142A2 Fab
142A2-EQR Fab
anti-CD3/28/TL1A
anti-CD3/28
IL-13 concentration (ng/mL)
2.0
1.5
1.0
0.5
0.0
-2
-1
0
1
2
Log10[Ab] (nM)